首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

1577057

幽門螺旋桿菌檢測市場、機會、成長動力、產業趨勢分析與預測，2024-2032

Helicobacter Pylori Testing Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年08月07日 | 出版商:

Global Market Insights Inc. | 英文 110 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2023年，全球幽門螺旋桿菌（H. Pylori）檢測市值為4.83億美元，預計在預測期內成長率為6.8%。這一成長的推動因素包括胃腸道疾病的盛行率不斷上升、對即時檢測 (PoC) 檢測的需求不斷成長以及非侵入性幽門螺旋桿菌檢測的日益普及。

導致市場擴張的一個主要因素是胃潰瘍病例的增加，這通常是由幽門螺旋桿菌感染引起的。壓力、吸煙和過度使用非類固醇抗發炎藥物 (NSAID) 等因素導致胃潰瘍發病率增加，從而刺激了對診斷測試的需求。根據美國胃腸病學會 (AGA) 的數據，70-90% 的消化性潰瘍患者體內都存在幽門螺旋桿菌，凸顯了檢測在管理潰瘍相關疾病方面的關鍵作用。

幽門螺旋桿菌檢測包括各種診斷程序，以檢測胃腸道中細菌的存在。這種細菌與消化性潰瘍、慢性胃炎以及某些情況下的胃癌等疾病有關。準確的檢測有助於診斷感染、指導治療和監測治療效果。

市場依測試類型分為侵入性測試和非侵入性測試，到2023年，非侵入性測試將佔據主導地位，佔56.6%的市場佔有率。測驗（SAT）因其不適感最小、見效快且適合所有年齡層而受到青睞。這些優勢使非侵入性檢測成為醫療保健提供者的熱門選擇，從而促進了細分市場的成長。

該市場按方法進一步分為 PoC 和實驗室測試，後者佔據最大的市場佔有率，2023 年價值 3.006 億美元。）具有高靈敏度和特異性，在準確診斷幽門螺旋桿菌感染和監測抗生素抗藥性方面發揮至關重要的作用。

就最終用途而言，診斷實驗室在 2023 年佔據市場主導地位，預計到 2032 年將達到 3.909 億美元。

2023年北美幽門螺旋桿菌檢測市值為1.701億美元，預計複合年成長率為4.3%。該地區的市場成長是由胃癌盛行率上升和人們對幽門螺旋桿菌感染的認知不斷提高以及診斷技術不斷創新的支持所推動的。

產業生態系統分析
產業影響力
- 成長動力
  - 胃潰瘍盛行率上升
  - 面臨風險的老年人口不斷增加
  - 對即時檢測設備的需求不斷成長
  - 非侵入性幽門螺旋桿菌檢測的採用率不斷上升
- 產業陷阱與挑戰
  - 缺乏熟練的侵入性檢測專業人員
  - 對幽門螺旋桿菌感染缺乏認知
成長潛力分析
報銷場景
監管環境
技術景觀
定價分析
波特的分析
PESTEL分析
差距分析
未來市場趨勢

第 4 章：競爭格局

介紹
公司矩陣分析
公司市佔率分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按測試類型，2021 - 2032 年

主要趨勢
侵入性
- 組織學
- 尿素酶快速檢測
- 惠普文化
非侵入性
- 血清學檢測
- 尿素呼氣試驗
- 糞便/糞便抗原測試

第 6 章：市場估計與預測：依方法，2021 - 2032

主要趨勢
照護端 (POC) 測試
基於實驗室的測試

第 7 章：市場估計與預測：按最終用途，2021 - 2032 年

主要趨勢
醫院
診所
診斷實驗室
其他最終用戶

第 8 章：市場估計與預測：按地區，2021 - 2032

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 9 章：公司簡介

Abbott Laboratories
Advance Pharma
Avanos Corporate
Biohit Oyj
bioMerieux SA
Bio-Rad Laboratories, Inc.
Cardinal Health, Inc.
Epitope Diagnostics
Gulf Coast Scientific
Laboratory Corporation of America, Inc.
Medline Industries
Meridian Biosciences, Inc.
Quidel Corporation
TECHLAB, Inc
Thermo Fischer Scientific Corporation

簡介目錄

Product Code: 4408

The Global Helicobacter Pylori (H. Pylori) Testing Market was valued at USD 483 million in 2023, with a projected growth rate of 6.8% over the forecast period. This growth is driven by the increasing prevalence of gastrointestinal disorders, a rising demand for point-of-care (PoC) testing, and the growing adoption of non-invasive H. pylori tests.

A major factor contributing to the market's expansion is the rise in gastric ulcer cases, often caused by H. pylori infections. Factors such as stress, smoking, and the overuse of nonsteroidal anti-inflammatory drugs (NSAIDs) contribute to the increased incidence of gastric ulcers, fueling the demand for diagnostic testing. According to the American Gastroenterological Association (AGA), H. pylori is present in 70-90% of patients with peptic ulcers, highlighting the critical role of testing in managing ulcer-related conditions.

H. pylori testing encompasses various diagnostic procedures to detect the presence of the bacterium in the gastrointestinal tract. This bacterium is associated with conditions such as peptic ulcers, chronic gastritis, and, in some cases, gastric cancer. Accurate testing aids in diagnosing infections, guiding treatment, and monitoring therapy effectiveness.

The market is segmented by test type into invasive and non-invasive tests, with the non-invasive segment holding a dominant 56.6% market share in 2023. Non-invasive tests like the urea breath test (UBT) and stool antigen test (SAT) are preferred for their minimal discomfort, rapid results, and suitability for all age groups. These advantages make non-invasive tests a popular choice among healthcare providers, contributing to segment growth.

The market is further categorized by method into PoC and laboratory-based tests, with the latter accounting for the largest market share, valued at USD 300.6 million in 2023. Laboratory-based tests, such as polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay (ELISA), offer high sensitivity and specificity, playing a crucial role in accurately diagnosing H. pylori infections and monitoring antibiotic resistance.

In terms of end use , diagnostic laboratories dominated the market in 2023 and are expected to reach USD 390.9 million by 2032. These laboratories offer specialized testing services, aiding in timely diagnoses and effective treatment planning.

The North American H. pylori testing market was valued at USD 170.1 million in 2023, with a projected CAGR of 4.3%. The region's market growth is driven by the rising prevalence of gastric cancers and growing awareness of H. pylori infections, supported by ongoing innovations in diagnostic technologies.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rise in prevalence of gastric ulcer
  - 3.2.1.2 Increasing geriatric population at risk
  - 3.2.1.3 Growing demand for point-of-care testing devices
  - 3.2.1.4 Rising adoption of non-invasive H. pylori testing
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 Lack of skilled professionals for invasive testing
  - 3.2.2.2 Lack of awareness regarding H. pylori infection
3.3 Growth potential analysis
3.4 Reimbursement scenario
3.5 Regulatory landscape
3.6 Technology landscape
3.7 Pricing analysis
3.8 Porter's analysis
3.9 PESTEL analysis
3.10 Gap analysis
3.11 Future market trends

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Test Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Invasive
- 5.2.1 Histology
- 5.2.2 Rapid urease test
- 5.2.3 HP culture
5.3 Non-invasive
- 5.3.1 Serologic test
- 5.3.2 Urea breath test
- 5.3.3 Stool/fecal antigen test

Chapter 6 Market Estimates and Forecast, By Method, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Point of care (POC) tests
6.3 Laboratory based tests

Chapter 7 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospitals
7.3 Clinics
7.4 Diagnostic laboratories
7.5 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa